Aktienanalyse zu Kezar Life Sciences Inc (KZR)KZRKezar Life Sciences Inc

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The Company is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Kezar Life Sciences Inc (KZR) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The lack of significant trading signals, neutral trading trends, weak financial performance, and no recent positive news or catalysts make this stock less appealing for immediate investment. Holding or exploring other opportunities may be more prudent.

4 analysts cover KZR: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 6.00.